Biogen Inc (BIIB.OQ)
231.27USD
19 Jul 2019
$-0.00 (-0.00%)
$231.27
$232.86
$234.10
$231.20
478,208
834,682
$388.67
$216.13
About
Overall
| Beta: | 0.99 |
| Market Cap(Mil.): | $44,841.73 |
| Shares Outstanding(Mil.): | 193.89 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BIIB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 9.91 | 30.63 | 34.52 |
| EPS (TTM): | 23.33 | -- | -- |
| ROI: | 20.60 | 13.02 | 12.69 |
| ROE: | 33.64 | 14.18 | 17.17 |
NHS England, Biogen reach deal on pricey drug for deadly disorder
NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.
NHS England, Biogen reach deal on pricey drug for deadly disorder
NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.
UPDATE 1-NHS England, Biogen reach deal on pricey drug for deadly disorder
NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.
NHS England, Biogen reach deal on pricey drug for deadly disorder
NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.
AbbVie says Humira rivals from Biogen, Amgen most aggressive so far
AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.
AbbVie says Humira rivals from Biogen, Amgen most aggressive so far
April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.
Biogen dips as strategy post Alzheimer's setback fails to impress
Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.
Biogen dips as strategy post Alzheimer's setback fails to impress
Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.
UPDATE 3-Biogen dips as strategy post Alzheimer's setback fails to impress
* Co beats 1st-qtr profit and revenue estimates (Adds details from conference call, analyst comment)
Biogen first-quarter profit rises 20 percent
April 24 Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.
Estimates